Clinical Trial Update: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma [Phase 4]

View source ↗

Summary

An open-label, single-arm Phase 4 trial evaluating a short-duration infusion of obinutuzumab in patients with previously untreated advanced follicular lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Advanced Follicular Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2021-08-24